ANEB
Anebulo·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ANEB
Anebulo Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that developing novel solutions for acute cannabinoid intoxication and substance abuse
1017 Ranch Road 620 South, Suite 107, Lakeway, Texas 78734
--
Anebulo Pharmaceuticals, Inc., was incorporated in Delaware on April 23, 2020. They are a clinical-stage biotechnology company developing treatments for cannabis toxicity such as unintentional cannabis poisoning, acute cannabinoid poisoning (" ACI ") and broader acute cannabinoid-induced diseases. Their lead product candidate, selonabant (formerly ANEB-001), is designed to rapidly reverse the negative effects of cannabis toxicity and shorten recovery time.
Company Financials
EPS
ANEB has released its 2026 Q1 earnings. EPS was reported at -0.05, versus the expected -0.12, beating expectations. The chart below visualizes how ANEB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
